Anand K. Iyer
Research Subjects
Research Interests
Anand K. Iyer has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Abhimanyu Kumbara
Welldoc Inc., Columbia, USA
3 shared publications - Mansur Shomali
Welldoc Inc., Columbia, MD, USA
3 shared publications - Courtney R. Green
Medical Affairs Dexcom, Inc 6340 Sequence Dr 92121 San Diego San Diego CA CA USA
2 shared publications - Jennifer E. Layne
Dexcom, San Diego, CA, USA
2 shared publications - Keri Leone
Dexcom, Inc., 6340 Sequence Dr, San Diego, US
2 shared publications - Lauren H. Jepson
Dexcom, San Diego, CA, USA
2 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Association for Computing Machinery (ACM)
- p. 9510-9521
EventGlucose: A Benchmark for Continuous Glucose Monitoring Forecasting with Behavioral Event Context
Glucose forecasting is critical for diabetes management. Continuous glucose monitoring (CGM) provides real-time readings, but glucose values alone do not capture the behavioral events (meals, exercise, medication) that clinicians and patients use to make daily decisions. In spite of advances in time series foundation models and large language models (LLMs), systematic study of event-aware glucose forecasting remains limited, and how behavioral event context helps different model families remains unclear. We introduce EventGlucose, a benchmark where every task pairs glucose time series with behavioral event context; every task requires event context for accurate prediction. EventGlucose provides 60 task instances spanning demographics, event types, and 5 context conditions, from no context to detailed event descriptions. We evaluate 18 model configurations zero-shot, covering LLM-based forecasters, multimodal architectures, time series foundation models, and statistical baselines. We report Clarke Error Grid-weighted CRPS metrics that emphasize clinical risk zones. Our experiments reveal a Context Integration Gap : richer context can help, but most current models fail to use it. Only GPT-4o-mini improves with more context, gaining 9% from NoCtx to StandardEventInfo. Ten of twelve context-aware models degrade with detailed descriptions, by up to 78% in ct-CRPS. Context effects are also asymmetric: meal tasks benefit in 4 of 6 demographic subgroups, while exercise tasks benefit in none, suggesting failures depend on event type rather than on context generally. Larger models also tend to degrade more than smaller ones within each model family. Despite EventGlucose's balanced design, Type 1 diabetes and middle-aged patients remain harder to predict than other subgroups. EventGlucose is the first benchmark to evaluate time series foundation models and LLMs on event-aware glucose forecasting, and it shows where current models break down when behavioral context is available. The benchmark is available at https://github.com/JHU-CDHAI/EventGlucoseBench.
- 8 August 2026
- Published by Association for Computing Machinery (ACM)
- p. 9510-9521
Open AccessEventGlucose: A Benchmark for Continuous Glucose Monitoring Forecasting with Behavioral Event Context
Glucose forecasting is critical for diabetes management. Continuous glucose monitoring (CGM) provides real-time readings, but glucose values alone do not capture the behavioral events (meals, exercise, medication) that clinicians and patients use to make daily decisions. In spite of advances in time series foundation models and large language models (LLMs), systematic study of event-aware glucose forecasting remains limited, and how behavioral event context helps different model families remains unclear. We introduce EventGlucose, a benchmark where every task pairs glucose time series with behavioral event context; every task requires event context for accurate prediction. EventGlucose provides 60 task instances spanning demographics, event types, and 5 context conditions, from no context to detailed event descriptions. We evaluate 18 model configurations zero-shot, covering LLM-based forecasters, multimodal architectures, time series foundation models, and statistical baselines. We report Clarke Error Grid-weighted CRPS metrics that emphasize clinical risk zones. Our experiments reveal a Context Integration Gap : richer context can help, but most current models fail to use it. Only GPT-4o-mini improves with more context, gaining 9% from NoCtx to StandardEventInfo. Ten of twelve context-aware models degrade with detailed descriptions, by up to 78% in ct-CRPS. Context effects are also asymmetric: meal tasks benefit in 4 of 6 demographic subgroups, while exercise tasks benefit in none, suggesting failures depend on event type rather than on context generally. Larger models also tend to degrade more than smaller ones within each model family. Despite EventGlucose's balanced design, Type 1 diabetes and middle-aged patients remain harder to predict than other subgroups. EventGlucose is the first benchmark to evaluate time series foundation models and LLMs on event-aware glucose forecasting, and it shows where current models break down when behavioral context is available. The benchmark is available at https://github.com/JHU-CDHAI/EventGlucoseBench.
- Open Access
- 11 September 2023
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 8 (1) , e47638
Impact of a Combined Continuous Glucose Monitoring–Digital Health Solution on Glucose Metrics and Self-Management Behavior for Adults With Type 2 Diabetes: Real-World, Observational Study
Background: The BlueStar (Welldoc) digital health solution for people with diabetes incorporates data from multiple devices and generates coaching messages using artificial intelligence. The BlueStar app syncs glucose data from the G6 (Dexcom) real-time continuous glucose monitoring (RT-CGM) system, which provides a glucose measurement every 5 minutes. Objective: The objective of this real-world study of people with type 2 diabetes (T2D) using the digital health solution and RT-CGM was to evaluate change in glycemic control and engagement with the program over 3 months. Methods: Participants were current or former enrollees in an employer-sponsored health plan, were aged 18 years or older, had a T2D diagnosis, and were not using prandial insulin. Outcomes included CGM-based glycemic metrics and engagement with the BlueStar app, including logging medications taken, exercise, food details, blood pressure, weight, and hours of sleep. Results: Participants in the program that met our analysis criteria (n=52) were aged a mean of 53 (SD 9) years; 37% (19/52) were female and approximately 50% (25/52) were taking diabetes medications. The RT-CGM system was worn 90% (SD 8%) of the time over 3 months. Among individuals with suboptimal glycemic control at baseline, defined as mean glucose >180 mg/dL, clinically meaningful improvements in glycemic control were observed, including reductions in a glucose management indicator (–0.8 percentage points), time above range 181-250 mg/dL (–4.4 percentage points) and time above range >250 mg/dL (–14 percentage points; all P<.05). Time in range 70-180 mg/dL also increased by 15 percentage points (P=.016) in this population, which corresponds to an increase of approximately 3.5 hours per day in the target range. Over the 3-month study, 29% (15/52) of participants completed at least one engagement activity per week. Medication logging was completed most often by participants (23/52, 44%) at a rate of 12.1 (SD 0.8) events/week, and this was closely followed by exercise and food logging. Conclusions: The combination of an artificial intelligence–powered digital health solution and RT-CGM helped people with T2D improve their glycemic outcomes and diabetes self-management behaviors.
- 11 September 2023
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 8 (1) , e47638
Open AccessImpact of a Combined Continuous Glucose Monitoring–Digital Health Solution on Glucose Metrics and Self-Management Behavior for Adults With Type 2 Diabetes: Real-World, Observational Study
Background: The BlueStar (Welldoc) digital health solution for people with diabetes incorporates data from multiple devices and generates coaching messages using artificial intelligence. The BlueStar app syncs glucose data from the G6 (Dexcom) real-time continuous glucose monitoring (RT-CGM) system, which provides a glucose measurement every 5 minutes. Objective: The objective of this real-world study of people with type 2 diabetes (T2D) using the digital health solution and RT-CGM was to evaluate change in glycemic control and engagement with the program over 3 months. Methods: Participants were current or former enrollees in an employer-sponsored health plan, were aged 18 years or older, had a T2D diagnosis, and were not using prandial insulin. Outcomes included CGM-based glycemic metrics and engagement with the BlueStar app, including logging medications taken, exercise, food details, blood pressure, weight, and hours of sleep. Results: Participants in the program that met our analysis criteria (n=52) were aged a mean of 53 (SD 9) years; 37% (19/52) were female and approximately 50% (25/52) were taking diabetes medications. The RT-CGM system was worn 90% (SD 8%) of the time over 3 months. Among individuals with suboptimal glycemic control at baseline, defined as mean glucose >180 mg/dL, clinically meaningful improvements in glycemic control were observed, including reductions in a glucose management indicator (–0.8 percentage points), time above range 181-250 mg/dL (–4.4 percentage points) and time above range >250 mg/dL (–14 percentage points; all P<.05). Time in range 70-180 mg/dL also increased by 15 percentage points (P=.016) in this population, which corresponds to an increase of approximately 3.5 hours per day in the target range. Over the 3-month study, 29% (15/52) of participants completed at least one engagement activity per week. Medication logging was completed most often by participants (23/52, 44%) at a rate of 12.1 (SD 0.8) events/week, and this was closely followed by exercise and food logging. Conclusions: The combination of an artificial intelligence–powered digital health solution and RT-CGM helped people with T2D improve their glycemic outcomes and diabetes self-management behaviors.
- Open Access
- 28 March 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Impact of a Combined Continuous Glucose Monitoring–Digital Health Solution on Glucose Metrics and Self-Management Behavior for Adults With Type 2 Diabetes: Real-World, Observational Study (Preprint)
BACKGROUND The BlueStar (Welldoc) digital health solution for people with diabetes incorporates data from multiple devices and generates coaching messages using artificial intelligence. The BlueStar app syncs glucose data from the G6 (Dexcom) real-time continuous glucose monitoring (RT-CGM) system, which provides a glucose measurement every 5 minutes. OBJECTIVE The objective of this real-world study of people with type 2 diabetes (T2D) using the digital health solution and RT-CGM was to evaluate change in glycemic control and engagement with the program over 3 months. METHODS Participants were current or former enrollees in an employer-sponsored health plan, were aged 18 years or older, had a T2D diagnosis, and were not using prandial insulin. Outcomes included CGM-based glycemic metrics and engagement with the BlueStar app, including logging medications taken, exercise, food details, blood pressure, weight, and hours of sleep. RESULTS Participants in the program that met our analysis criteria (n=52) were aged a mean of 53 (SD 9) years; 37% (19/52) were female and approximately 50% (25/52) were taking diabetes medications. The RT-CGM system was worn 90% (SD 8%) of the time over 3 months. Among individuals with suboptimal glycemic control at baseline, defined as mean glucose >180 mg/dL, clinically meaningful improvements in glycemic control were observed, including reductions in a glucose management indicator (–0.8 percentage points), time above range 181-250 mg/dL (–4.4 percentage points) and time above range >250 mg/dL (–14 percentage points; all P<.05). Time in range 70-180 mg/dL also increased by 15 percentage points (P=.016) in this population, which corresponds to an increase of approximately 3.5 hours per day in the target range. Over the 3-month study, 29% (15/52) of participants completed at least one engagement activity per week. Medication logging was completed most often by participants (23/52, 44%) at a rate of 12.1 (SD 0.8) events/week, and this was closely followed by exercise and food logging. CONCLUSIONS The combination of an artificial intelligence–powered digital health solution and RT-CGM helped people with T2D improve their glycemic outcomes and diabetes self-management behaviors.
- 28 March 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImpact of a Combined Continuous Glucose Monitoring–Digital Health Solution on Glucose Metrics and Self-Management Behavior for Adults With Type 2 Diabetes: Real-World, Observational Study (Preprint)
BACKGROUND The BlueStar (Welldoc) digital health solution for people with diabetes incorporates data from multiple devices and generates coaching messages using artificial intelligence. The BlueStar app syncs glucose data from the G6 (Dexcom) real-time continuous glucose monitoring (RT-CGM) system, which provides a glucose measurement every 5 minutes. OBJECTIVE The objective of this real-world study of people with type 2 diabetes (T2D) using the digital health solution and RT-CGM was to evaluate change in glycemic control and engagement with the program over 3 months. METHODS Participants were current or former enrollees in an employer-sponsored health plan, were aged 18 years or older, had a T2D diagnosis, and were not using prandial insulin. Outcomes included CGM-based glycemic metrics and engagement with the BlueStar app, including logging medications taken, exercise, food details, blood pressure, weight, and hours of sleep. RESULTS Participants in the program that met our analysis criteria (n=52) were aged a mean of 53 (SD 9) years; 37% (19/52) were female and approximately 50% (25/52) were taking diabetes medications. The RT-CGM system was worn 90% (SD 8%) of the time over 3 months. Among individuals with suboptimal glycemic control at baseline, defined as mean glucose >180 mg/dL, clinically meaningful improvements in glycemic control were observed, including reductions in a glucose management indicator (–0.8 percentage points), time above range 181-250 mg/dL (–4.4 percentage points) and time above range >250 mg/dL (–14 percentage points; all P<.05). Time in range 70-180 mg/dL also increased by 15 percentage points (P=.016) in this population, which corresponds to an increase of approximately 3.5 hours per day in the target range. Over the 3-month study, 29% (15/52) of participants completed at least one engagement activity per week. Medication logging was completed most often by participants (23/52, 44%) at a rate of 12.1 (SD 0.8) events/week, and this was closely followed by exercise and food logging. CONCLUSIONS The combination of an artificial intelligence–powered digital health solution and RT-CGM helped people with T2D improve their glycemic outcomes and diabetes self-management behaviors.